We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Gut Regulated Associations of Neuronal Signalling in High Blood Pressure (GRAINS-BP): a double-blinded randomised crossover placebo-controlled trial
AI summary Read the abstract
Nearly a third of Australian adults have high blood pressure, and many struggle to control it with medication alone—so researchers are testing whether a special type of fiber (found in a modified corn starch) can help by boosting gut bacteria that produce beneficial compounds called short-chain fatty acids. This trial will investigate whether these gut-produced compounds lower blood pressure by calming an overactive nervous system, which could offer a diet-based tool to complement medications. The study will also check for other health markers, including gut health and even levels of microplastics in the blood, but results aren't in yet—this paper describes the study's design, not its findings
Hypertension affects 1 in 3 Australian adults and is a major contributor to stroke and myocardial infarction. Despite the availability of various medications, over 50% of patients struggle to control their blood pressure (BP) due to nonadherence, difficulty finding the right treatment, or avoidance of medication. Diet plays a key role in cardiovascular health, with high-fiber intake shown to lower BP through the production of short-chain fatty acids (SCFAs), metabolites formed during fiber fermentation. A previous clinical trial found that incorporating a specific type of resistant starch – high amylose maize starch enriched with acetate and butyrate (HAMSA/B) — significantly reduced blood pressure in hypertensive patients. While the exact mechanism remains unclear, SCFAs may influence BP via the gut-brain axis by reducing muscle sympathetic nerve activity (MSNA), which has vasoconstrictor function and is elevated in hypertensive individuals. The GRAINS-BP clinical trial will recruit 29 adults with untreated hypertension (≥ 140/90 mmHg) for a double-blind, cross-over study using HAMSA/B administered as a shake delivered twice daily. The assessment period will span 48 days and include four visits at the Alfred Hospital, Melbourne, Australia. At visit 1, baseline measurement will be taken, including muscle sympathetic nerve activity (MSNA) and electrocardiogram (ECG). Participants will be randomised to the order in which they receive the placebo and HAMSA/B shake. Each intervention period will last 14 days, separated by a 20-day washout before participants cross over to the alternate treatment. At each visit, faecal, urine, and blood samples will be collected to investigate microbiome, cardiometabolic, renal, and immune profiles, respectively. Univariate and multivariate statistical analyses will be conducted to examine treatment effects and to identify correlations among microbiome, cardiometabolic, renal, and immune outcomes. This project’s primary outcome is change in autonomic nervous system activity. Secondary outcomes include 24-h BP, gut microbiome composition, SCFA levels, immune cell profiles gastrointestinal transit time, quality of life, anxiety and depression symptoms, cognitive function, gut barrier integrity, and circulating micro- and nanoplastics. Findings from this study will reveal whether SCFAs reduce blood pressure by their influence on the autonomic nervous system. This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12625000557437).
More Papers Like This
The influence of microplastics on hypertension-associated cardiovascular injury via the modulation of gut microbiota
AI summary Read the abstract
Researchers found that people with high blood pressure had more microplastics in their stool samples than healthy individuals, and feeding microplastics to mice raised their blood pressure and caused heart damage. The harm was linked to changes in gut bacteria, and a high-fiber diet or antibiotics helped reduce the damage. This study suggests microplastic exposure may worsen heart and blood pressure problems by disrupting the gut microbiome.
Resveratrol Butyrate Esters Reduce Hypertension in a Juvenile Rat Model of Chronic Kidney Disease Exacerbated by Microplastics
AI summary Read the abstract
Researchers found that resveratrol butyrate esters reduced high blood pressure in young rats that had both chronic kidney disease and microplastic exposure. The protective effects worked by improving nitric oxide levels, regulating the body's blood pressure control system, and positively shifting gut bacteria composition. The study suggests that certain natural compounds may help counteract the cardiovascular harm associated with microplastic exposure.
Fighting microplastics: The role of dietary fibers in protecting health
AI summary Read the abstract
This review examines how microplastics entering the body through food may affect gastrointestinal health and explores whether dietary fibers could help reduce those risks. Researchers found that dietary fibers may help mitigate the harmful effects of microplastics through mechanisms related to their size, concentration, and composition, though the evidence is still limited. The study calls for more research into using dietary strategies as a practical approach to reducing the health impact of microplastic ingestion.
Abstract P179: Nano- And Microplastic-enriched Diets Affect Inflammation And Target Organ Damage In Hypertension
AI summary Read the abstract
This study found that diets enriched with nano- and microplastics increase inflammation and worsen organ damage in rats with high blood pressure. The findings suggest that microplastic exposure may be particularly harmful for people who already have cardiovascular conditions, potentially accelerating disease progression through inflammatory pathways.
Epigallocatechin-3-gallate ameliorates polystyrene microplastics-induced anxiety-like behavior in mice by modulating gut microbe homeostasis
AI summary Read the abstract
A mouse study found that exposure to polystyrene microplastics caused anxiety-like behavior by disrupting gut bacteria and triggering brain inflammation. A green tea compound called EGCG (epigallocatechin-3-gallate) reversed these effects by restoring healthy gut microbe balance and reducing inflammation in the brain. This suggests the gut-brain connection plays a key role in how microplastics affect mental health, and that certain dietary compounds might offer protection.
Research digests by email
When a large batch of papers lands in the Atlas, we read through it and send a short write-up of what stood out.